Commentary: Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both IPF and non-IPF
نویسندگان
چکیده
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic fibrosing interstitial lung disease associated with pattern Usual Interstitial Pneumonia (UIP) based on CT appearances or histology.
منابع مشابه
The questionable efficacy of pirfenidone in IPF.
Azuma and colleagues (1) report that pirfenidone treatment improves vital capacity and prevents acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF) but fails to improve endexercise hypoxemia in this population. Given the paucity of data from randomized, controlled trials in IPF, this investigation might have added important information regarding a promising therapy. Unfortu...
متن کاملColitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
A 76-year-old Japanese man was diagnosed with idiopathic pulmonary fibrosis (IPF) based on high-resolution computed tomography (CT) (Picture A) three years prior. Nintedanib (300 mg/day) treatment was initiated to treat the IPF. Eighty-four days later, he visited our hospital with stomachache, chronic diarrhea and gross hematochezia. Abdominal contrast-enhanced CT showed bowel wall thickening (...
متن کاملNintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. The molecular mechanisms involved in the progression of IPF are not fully understood; however, the platelet-derived growth factor (PDGF)/PDGF receptor pathway is thought to play a critical role in fibrogenesis of the lungs. Other growth factors, including fibroblast growth factor and vascular endothelial growth fa...
متن کاملDo all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
Idiopathic pulmonary fibrosis (IPF) is an incurable condition that is characterized by progressive pulmonary fibrosis, architectural distortion of the lung and loss of gas exchange units. Until recently, there was no effective treatment for this condition. However, there were two landmark trials published earlier this year, which have changed the management of this condition. Pirfenidone (Asses...
متن کاملSwitching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF.
References 1 Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl. 25, D34–D41. 2 von Herbay A, Illes A, Waldherr R, et al. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer 1990; 66: 587–592. 3 Dorfmuller P, Gunther S, Ghigna MR, et al. Microvascular disease in chronic thromboemboli...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of lung health and diseases
سال: 2022
ISSN: ['2689-999X']
DOI: https://doi.org/10.29245/2689-999x/2022/1.1180